HUMA

Humacyte is a pre-commercial tissue-engineering story that lives or dies on Symvess (its acellular tissue-engineered vessel) and the V007/V012 Phase 3 programs — the 10-K's forward-looking section is almost entirely 'plans and ability to commercialize,' 'obtain marketing approvals,' and 'how long our existing cash will be sufficient.' The numbers say the runway is the whole ballgame: FY2025 revenue was just $2.04M against a $108M operating loss and -$105M operating cash flow, while cash and equivalents stood at only $50.5M. That is roughly six months of burn. Management explicitly flags 'cost-saving measures' and the risk of 'further actions or additional asset impairment charges,' which is what a company says when it is out over its skis on cash.

The headline 'improvement' is a trap. Net income of -$40.8M looks 72.5% better YoY, but operating income barely moved (-$108M, +5.5%) and operating cash flow actually worsened (-$105M, -7.1%) — the net-loss narrowing is non-operating (below-the-line, likely fair-value/derivative swings), not a real turn in the business. Meanwhile shares outstanding jumped 43.1% to 222M, so existing holders were already heavily diluted, and stockholders' equity is a razor-thin $3.11M against $113M of liabilities (36x leverage) with a -$727M accumulated deficit. Given the cash position and burn, another dilutive raise is close to a certainty, and at $0.71 it will be issued cheap.